Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience. 2015

Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
*Cleveland Clinic Lerner College of Medicine, Rose Ella Burkhardt Brain Tumor Neuro-Oncology Center, Neurological Institute †Radiation Oncology ‡Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

BACKGROUND Cerebral radiation necrosis (RN) is a devastating complication of radiation therapy for brain tumors. Recent studies have explored the role of bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor in the treatment of RN of the brain. We report 24 patients with cerebral RN who were treated with bevacizumab. METHODS Twenty-four patients diagnosed with cerebral RN and treated with different schedules of bevacizumab between July 2007 and June 2012, were identified from the Cleveland Clinic Brain Tumor and Neuro-Oncology Center's database. Pretreatment and posttreatment magnetic resonance imaging (MRI) studies were compared to evaluate bevacizumab efficacy. RESULTS Posttreatment MRI demonstrated a radiographic improvement in 23 of 24 patients on the postcontrast T1-weighted MRI and fluid-attenuated inversion-recovery sequences. Using the McDonald criteria, the average change in the T1-weighted postcontrast MRI was a decrease of 48.1%, and the average change in the fluid-attenuated inversion-recovery images was a decrease of 53.7%. There was a mean daily dose reduction of 9.4 mg of dexamethasone after initiation of bevacizumab in patients who were on steroids at the start of bevaciuzmab therapy for RN. Treatment with bevacizumab was well tolerated with only 1 grade 3 adverse event. CONCLUSIONS The current study demonstrates that bevacizumab treatment results in excellent clinical and radiologic response in patients with RN caused by common forms of radiation therapy. The safety profile of bevacizumab use in RN is acceptable. In the current study, we found no difference between different schedules of bevacizumab in treatment outcomes.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D011832 Radiation Injuries Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES. Radiation Sickness,Radiation Syndrome,Injuries, Radiation,Injury, Radiation,Radiation Injury,Radiation Sicknesses,Radiation Syndromes,Sickness, Radiation,Sicknesses, Radiation,Syndrome, Radiation,Syndromes, Radiation
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
August 2009, Journal of neuro-oncology,
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
December 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
August 2012, European journal of medical research,
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
January 2017, Recent patents on anti-cancer drug discovery,
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
March 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
February 2011, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
September 2023, Journal of Korean Neurosurgical Society,
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
September 2013, American heart journal,
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
February 1989, The Journal of urology,
Neda H Sadraei, and Saurabh Dahiya, and Samuel T Chao, and Erin S Murphy, and Kwabena Osei-Boateng, and Hao Xie, and John H Suh, and David M Peereboom, and Glen H J Stevens, and Manmeet S Ahluwalia
January 1993, Cleveland Clinic journal of medicine,
Copied contents to your clipboard!